Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.66 |
| ▸ | PDE5A | O76074 | 9/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13986185 | 0.86 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7436271 | 0.86 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL9502308 | 0.80 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| Cipamfylline SCHEMBL26990 | 0.79 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7026234 | 0.79 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7809025 | 0.79 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7395750 | 0.78 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL13986119 | 0.78 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7027210 | 0.78 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7025747 | 0.77 | ADORA1 (0.64) | PDE4APDE4BPDE4CPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459479-B2 | Benzylated PDE4 inhibitors | BIOLIPOX AB (SE) | 2008-12-02 | — | — | US | disclosed |
| US-20080287522-A1 | reduced or no emetogenic effects ; benzylated phosphodiesterase 4 inhibitors; e.g. Rolipram, Ariflo, Arofylline; preparation by benzylation using benzyl bromide or a derivative; antiinflammatory agents; to treat autoimmune diseases; cystic fibrosis | BIOLIPOX AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-7446129-B2 | Benzylated PDE4 inhibitors | BIOLIPOX AB (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20070208181-A1 | BENZYLATED PDE4 INHIBITORS | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2007-09-06 | — | — | US | disclosed |
| EP-1813284-A1 | PHARMACEUTICAL COMPOSITION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287522-A1 | reduced or no emetogenic effects ; benzylated phosphodiesterase 4 inhibitors; e.g. Rolipram, Ariflo, Arofylline; preparation by benzylation using benzyl bromide or a derivative; antiinflammatory agents; to treat autoimmune diseases; cystic fibrosis | PDE4B, PDE4A, PDE7A | PDE4A 2/4885PDE4B 1/4885PDE4C 4/4885 |
| US-20070208181-A1 | BENZYLATED PDE4 INHIBITORS | PDE4B, PDE4A, PDE3B | PDE4A 2/4885PDE4B 1/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.